All News
Does Evusheld shield people living with rheumatic diseases?
While COVID vaccination and subsequent booster remain the cornerstone, pre-exposure prophylaxis such as Evusheld (tixagevimab and cilgavimab) has been approved by FDA in December 2021 and EMA in March 2022 for people immunocompromised either due to a medical condition or receiving treatment with immunosuppressants and may not mount an adequate immune response to COVID vaccination. How does this therapy fare in RMD patients?
Read Article
Inverse association between average yearly HCQ dose and CV damage in cohort of SLE pts from Abs 0982 #ACR22 @RheumNow https://t.co/sfB6ONgwOa https://t.co/FAUGAVe2mB
Dr. Rachel Tate uptoTate ( View Tweet)
Curtis et al @RADoctor . IL6i more effective than conventional immunomodulators in refractory PMR. More likely to discontinue GC (HR 1.32), minimal GC (<2mg) (HR 1.30). @RheumNow #ACR22 Abstr#1547 https://t.co/uzSzrLQ9cB https://t.co/G4pEkOgYm2
Richard Conway RichardPAConway ( View Tweet)
Alle et al. ITP develops into SLE 5.6/1000py. 5.4% of ITP in this study developed SLE after 1801.4py follow up. Assoc refractory ITP, low complement, cytopenias, LA, hypergamma, high titre ANA. @RheumNow #ACR22 Abstr#1455 https://t.co/ORTeB0Q9Pi https://t.co/AVo97uMbpW
Richard Conway RichardPAConway ( View Tweet)
Nice RS3PE irAE description from CanRIO
Two of my RS3PE irAE pts: both severe Sx
one in 2018: not enough PNL until palliation & suffered until then
one in 2022: prompt diagnosis, right PNL dose, living v well now
Hopefully we always continue to improve
ASBT0758 #ACR22 @RheumNow https://t.co/5Ps2HRllNC
David Liew drdavidliew ( View Tweet)
A diagnostic delay of 6 months of #psoriaticarthritis was assoc w/
⬆️incidence of depression
⬆️limitation in participation of social roles & activities
⬆️impact on QoL
in this study by George Gondo @NPF & team
🔖Take home msg: Early dx of PsA is key!
#ACR22 @RheumNow ABST1507 https://t.co/wIZT4MKV4b
sheila RHEUMarampa ( View Tweet)
TMP-SMX PPX dispensed to less than a quarter of GPA pts at the time of RTX. Recent GC had the greatest association w/ PPX. Do you prescribe PPX for your GPA pts #Rheumtwitter? Abs 1071 #ACR22 @RheumNow https://t.co/qJyuGATtJo https://t.co/w4UaGgjEW1
Dr. Rachel Tate uptoTate ( View Tweet)
Shall we cycle TNFi in AxSpA?
CorEvitas registry 86 pts
70% TNFi monotherapy, 23% NSAIDs, 42% high & 24% v high DA
Cycling to 2nd line TNFi
At 6 months: very low achievement of ASDAS-LDA (15%), MCID in ASDAS (7%) & no MI.
https://t.co/S9vnz5PXuX
Abs#1499 #ACR22 @Rheumnow https://t.co/1IZIYcPCBz
Aurelie Najm AurelieRheumo ( View Tweet)
Pan et al 11beta-hydroxysteroid dehydrogenase inhibitor SPI-62 mitigates glucocorticoid toxicity in mouse model. Human trial in PMR ongoing. @RheumNow #ACR22 Abstr#1549 https://t.co/t74Hazll9H https://t.co/4425RUwIz4
Richard Conway RichardPAConway ( View Tweet)
Mepolizumab assoc'd w/ clinical benefits in EGPA, including in patients w/ and w/o a vasculitic phenotype. Abs 1074 #ACR22 @RheumNow https://t.co/VCGhGaci8b https://t.co/OV8A1vsx1G
Dr. Rachel Tate uptoTate ( View Tweet)
Filho et al. Retrospective Brazilian study. ADA vs LEF in Takayasu arteritis. Comparable renission, relapses, steroid dose, ESR, CRP, imaging over median 15 weeks. More AEs in LEF but non-severe. @RheumNow #ACR22 Abstr#1553 https://t.co/499dUNmpUD https://t.co/AEk5cG7dc4
Richard Conway RichardPAConway ( View Tweet)
Juge @Juge_P_A @PhilippeDieude et al. RA-ILD patients have shorter telomere length than RA without ILD. RA-ILD similar telomere length to IPF. OR 0.54 for RA-ILD. Assoc with FVC%pred also. @RheumNow #ACR22 Abstr#1122 https://t.co/H5A7unpjjB https://t.co/IjvHmupykM
Richard Conway RichardPAConway ( View Tweet)
Del-Río-Guerrero et al. Sphygmomanometry-induced allodynia for fibromyalgia detection. 62% sensitivity and 84% specificity. Much pain = 23% sensitivity and 96% specificity. Only seems to apply in female patients. @RheumNow #ACR22 Abstr#1225 https://t.co/zCHfmvwOcn https://t.co/tjBBny0WSR
Richard Conway RichardPAConway ( View Tweet)
Abstr 1255 Do Rheumatologists overcall sacroiliitis on imaging in axSpA?
Compared to central readers:
-Agreement w/ local readers = 87% agreement (X-Rays); 74.5% (MRIs)
- Agreement w/ Academic rheumatologists was greater vs community rheumatologists
#ACR22 @RheumNow https://t.co/j2vFoKA3n0
Akhil Sood MD AkhilSoodMD ( View Tweet)
Study by Dr EPapachristodoulou on
features of #lupus pts w/ LAD: myo/pericarditis, cytopenias, nephritis,⬆️markers
Those w/LN biopsy: reactive(66.7%) vs. necrotizing(33.3%) pattern
👉Pts w/ necrotizing pattern: unexplained fevers, sicca& malar rash.
#ACR22 @RheumNow ABST1443 https://t.co/J4aMRnYk8N
sheila RHEUMarampa ( View Tweet)
Avacopan's efficacy and safety profiles support use in AAV in Abs 1077 #ACR22 @RheumNow https://t.co/Zp05ofTgFP https://t.co/zA2sIEfYCS
Dr. Rachel Tate uptoTate ( View Tweet)
Join us for our daily topic panels--we'll be live on Twitter, LinkedIn, FB and YouTube OR sign up directly below. #ACR22
https://t.co/Oql4iv6RyO https://t.co/S4t7ucliUF
Links:
Dr. John Cush RheumNow ( View Tweet)
Much gusto for GUSTO: Efficacy of Tocilizumab Monotherapy for GCA
Dr. Richard Conway discusses abstract 0470 - being presented at the #ACR22 meeting.
https://t.co/btztbYWjq1 https://t.co/hrpZhIRLKO
Links:
Dr. John Cush RheumNow ( View Tweet)
Ab1115 #ACR22 Rx Co-Pay affects Rx Adherence in SLE
Higher copays associated w/:
💊39% lower odds of HCQ adherence
💊56% lower AZA adherence
💊32% lower MMF adherence
Need better $$ and transparency into costs. Screen for determinants of health affecting affordability!
@Rheumnow https://t.co/1NdBb3GLzL
Eric Dein ericdeinmd ( View Tweet)
Abs 0829 at #ACR22 finds AOSD more commonly affects caucasian females. Also notes abnormal labs include elevated inflammatory markers, leukocytosis, and anemia. @RheumNow https://t.co/1Nr8C5dX3G
Dr. Rachel Tate uptoTate ( View Tweet)